Micro<scp>RNA</scp>s in myeloid malignancies

Gordon, Jill; Wong, Justin; Rasko, John E.J.

doi:10.1111/bjh.12364

Cited by 41 publications

(36 citation statements)

References 148 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A high expression of MIR155 and of MIR3151 (Eisfeld et al, 2012) constitutes an independent adverse prognostic factor in CN-AML. Differential expression of a plethora of miRNAs are associated with different cytogenetically or molecular defined subsets of AML, however without proven prognostic significance (Gordon et al, 2013).…”

Section: Micro-rnasmentioning

confidence: 99%

Prognostic factors for acute myeloid leukaemia in adults - biological significance and clinical use

et al. 2014

View full text Add to dashboard Cite

Section: Micro-rnasmentioning

confidence: 99%

Prognostic factors for acute myeloid leukaemia in adults - biological significance and clinical use

et al. 2014

View full text Add to dashboard Cite

“…7,8 The importance of miRNAs is further supported by reports of deregulated expression of several miRNAs in hematologic malignancies. [9][10][11] However, functional analysis of miRNA in human as opposed to murine hematopoiesis has been challenging and is less well described.…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors

Wang

et al. 2015

Blood

127

101

View full text Add to dashboard Cite

show abstract

“…Gordon et al found hsa-miR-10a, hsa-miR-17/92, hsa-miR-150, hsa-miR-203 and hsa-miR-328 to be the most commonly deregulated miRNAs in CML (14). A miRNA may function as a tumour suppressor or an oncogene (15).…”

Section: Introductionmentioning

confidence: 99%

Preliminary data on microRNA expression profiles in a group of South African patients diagnosed with chronic myeloid leukaemia

Prinsloo

Pool

Niekerk

2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Micro-ribonucleic acids (miRNAs) are small functional non-coding RNAs that downregulate gene expression at the post-transcriptional level. Abnormal expression of specific miRNAs has been recorded in chronic lymphocytic leukaemia, other non-Hodgkin B-cell lymphomas, lung cancer and chronic myeloid leukaemia (CML). The aim of this study was to compare miRNA expression profiles among patients with newly diagnosed CML, those on established therapy with imatinib mesylate, and healthy individuals. The expression of 88 miRNAs was evaluated in a total of nine samples divided into three groups: Group 1 comprised three samples collected from newly diagnosed CML patients; group 2 consisted of three samples collected from patients on therapy; the remaining three samples were collected from healthy volunteers (control group). Total RNA was extracted from whole blood and reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) was performed on the LightCycler ® 480 platform using Human Serum & Plasma miRNA PCR Arrays. In group 1, only SNORD44 was downregulated, while hsa-miR-372 and hsa-miR-375 were found to be significantly upregulated compared with the control group. By contrast, 49 miRNAs were significantly upregulated in group 2 compared with the control group. miRNAs hsa-miR-106b, hsa-miR-21, hsa-miR-221, hsa-miR-10a, hsa-miR-193a-5p and hsa-miR-30e were expressed in group 2. Therefore, miRNA expression profiles differed between the two patient groups. IntroductionChronic myeloid leukaemia (CML) is an acquired disease resulting from the malignant transformation of a single stem cell, characterized by anaemia extreme blood granulocytosis and granulocytic immaturity (1). CML is triggered by a reciprocal translocation of the long arms of chromosomes 9 and 22, referred to as the Philadelphia chromosome (2). The breakpoint cluster region (BCR) gene on chromosome 22 and the Abelson murine leukaemia viral oncogene homolog 1 (ABL1) gene on chromosome 9 are involved in this t(9;22)(q34;q11) translocation leading to the formation of a new chimeric fusion oncogene, BCR-ABL1. Expression of this fusion oncogene produces an abnormal, elongated 8-kb ribonucleic acid (RNA) fragment, which is translated into a unique tyrosine phosphoprotein kinase, considered to be essential for the development of the leukaemic phenotype (1,3).Imatinib mesylate (Gleevec ® ; Novartis, Basel, Switzerland) has been established as the standard first-line therapy for CML (4,5). Response to therapy is defined as optimal, suboptimal, or failure of treatment. Optimal response is defined as follows: Complete haematological response [normal full blood count, minimal cytogenetic response (CyR) at 3 months]; partial cytogenetic response at 6 months; complete CyR (CCyR) at 12 months and major molecular response (≥3-log reduction in BCR-ABL1 transcripts) at 18 months (6).MicroRNAs (miRNAs) have recently been identified as a class of small functional non-coding RNAs of 18-25 nucleotides (7,8) which bind to the 3'-untranslated region of mRNAs, do...

show abstract

MicroRNAs in myeloid malignancies

Cited by 41 publications

References 148 publications

Prognostic factors for acute myeloid leukaemia in adults - biological significance and clinical use

Prognostic factors for acute myeloid leukaemia in adults - biological significance and clinical use

MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors

Preliminary data on microRNA expression profiles in a group of South African patients diagnosed with chronic myeloid leukaemia

Contact Info

Product

Resources

About